Literature DB >> 12911847

Isoprenoid metabolism and the pleiotropic effects of statins.

Ulrich Laufs1, James K Liao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12911847      PMCID： PMC2676316          DOI： 10.1007/s11883-003-0008-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  59 in total

1.  Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

Authors:  U Laufs; S Wassmann; S Hilgers; N Ribaudo; M Böhm; G Nickenig
Journal:  Am J Cardiol       Date:  2001-12-01       Impact factor: 2.778

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

Review 3.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

Authors:  M Takemoto; K Node; H Nakagami; Y Liao; M Grimm; Y Takemoto; M Kitakaze; J K Liao
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

5.  Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.

Authors:  Ulrich Laufs; Karen Gertz; Ulrich Dirnagl; Michael Böhm; Georg Nickenig; Matthias Endres
Journal:  Brain Res       Date:  2002-06-28       Impact factor: 3.252

6.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

7.  Lipid-lowering drug use and cardiovascular events after myocardial infarction.

Authors:  Olaf H Klungel; Susan R Heckbert; Anthonius de Boer; Hubert G M Leufkens; Sean D Sullivan; Paul A Fishman; David L Veenstra; Bruce M Psaty
Journal:  Ann Pharmacother       Date:  2002-05       Impact factor: 3.154

8.  Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.

Authors:  Galina K Sukhova; J Koudy Williams; Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

9.  Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.

Authors:  H Buchwald; R L Varco; J R Boen; S E Williams; B J Hansen; C T Campos; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink; H S Sawin
Journal:  Arch Intern Med       Date:  1998-06-08

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  23 in total

1.  Targeted therapy to prevent progression of calcific aortic stenosis.

Authors:  Nalini M Rajamannan; Catherine M Otto
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

Review 2.  Rho GTPases, statins, and nitric oxide.

Authors:  Yoshiyuki Rikitake; James K Liao
Journal:  Circ Res       Date:  2005-12-09       Impact factor: 17.367

Review 3.  Spectrum of pleiotropic effects of statins in heart failure.

Authors:  Nitin Mathur; Kumudha Ramasubbu; Douglas L Mann
Journal:  Heart Fail Clin       Date:  2008-04       Impact factor: 3.179

Review 4.  Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.

Authors:  Hugo Ribeiro Zanetti; Leonardo Roever; Alexandre Gonçalves; Elmiro Santos Resende
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

5.  Lovastatin inhibits the thrombin-induced loss of barrier integrity in bovine corneal endothelium.

Authors:  Mahesh Shivanna; Supriya S Jalimarada; Sangly P Srinivas
Journal:  J Ocul Pharmacol Ther       Date:  2010-02       Impact factor: 2.671

6.  Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis.

Authors:  Ximing Du; Ika Kristiana; Jenny Wong; Andrew J Brown
Journal:  Mol Biol Cell       Date:  2006-03-29       Impact factor: 4.138

Review 7.  Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Authors:  Benoit Chauvin; Sylvain Drouot; Aurélie Barrail-Tran; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

Review 8.  The role of statin therapy in the management of cardiomyopathies.

Authors:  Kumudha Ramasubbu; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

Review 9.  Should a statin be prescribed to every patient with heart failure?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; John A Goudevenos; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Heart Fail Rev       Date:  2007-08-12       Impact factor: 4.214

10.  BMPER is upregulated by statins and modulates endothelial inflammation by intercellular adhesion molecule-1.

Authors:  Thomas Helbing; René Rothweiler; Jennifer Heinke; Lena Goetz; Philipp Diehl; Andreas Zirlik; Cam Patterson; Christoph Bode; Martin Moser
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-30       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.